Maggie Tabberer
Overview
Explore the profile of Maggie Tabberer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1374
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Garcia-Aymerich J, Puhan M, Corriol-Rohou S, de Jong C, Demeyer H, Dobbels F, et al.
Thorax
. 2021 Jan;
76(3):228-238.
PMID: 33479044
Background: The Daily-PROactive and Clinical visit-PROactive Physical Activity (D-PPAC and C-PPAC) instruments in chronic obstructive pulmonary disease (COPD) combines questionnaire with activity monitor data to measure patients' experience of physical...
12.
Stott-Miller M, Mullerova H, Miller B, Tabberer M, El Baou C, Keeley T, et al.
Int J Chron Obstruct Pulmon Dis
. 2020 Oct;
15:2467-2476.
PMID: 33116463
Background: Chronic cough and phlegm are frequently reported chronic obstructive pulmonary disease (COPD) symptoms. Prior research classified chronic mucus hypersecretion (CMH) based on the presence of these symptoms for ≥3...
13.
Lee L, Bailes Z, Barnes N, Boulet L, Edwards D, Fowler A, et al.
Lancet Respir Med
. 2020 Sep;
9(1):69-84.
PMID: 32918892
Background: Despite inhaled corticosteroid plus long-acting β-agonist (ICS/LABA) therapy, 30-50% of patients with moderate or severe asthma remain inadequately controlled. We investigated the safety and efficacy of single-inhaler fluticasone furoate...
14.
Tabberer M, Jones C, Kilbride S, Halpin D, Lomas D, Pascoe S, et al.
Adv Ther
. 2020 Jul;
37(9):3775-3790.
PMID: 32647911
Introduction: The phase 3 InforMing the PAthway of COPD (chronic obstructive pulmonary disease) Treatment (IMPACT) trial, single-inhaler therapy with fluticasone furoate (FF) 100 μg, umeclidinium (UMEC) 62.5 μg, and vilanterol...
15.
Stanford R, Tabberer M, Kosinski M, Johnson P, White J, Carlyle M, et al.
Chronic Obstr Pulm Dis
. 2020 Jan;
7(1):26-37.
PMID: 31999900
Rationale: Uptake of the COPD Assessment Test (CAT) is not yet widespread in patients with chronic obstructive pulmonary disease (COPD) within U.S. primary care and its alignment with other assessments...
16.
Mullerova H, Dransfield M, Thomashow B, Jones P, Rennard S, Karlsson N, et al.
Am J Respir Crit Care Med
. 2019 Dec;
201(9):1058-1067.
PMID: 31815521
No abstract available.
17.
Worsley S, Snowise N, Halpin D, Midwinter D, Ismaila A, Irving E, et al.
ERJ Open Res
. 2019 Nov;
5(4).
PMID: 31720293
Effectiveness studies complement conventional randomised controlled trials by providing a holistic view of treatments in the setting of usual clinical practice. We present the protocol for the ongoing INTREPID (INvestigation...
18.
Naya I, Compton C, Ismaila A, Birk R, Brealey N, Tabberer M, et al.
ERJ Open Res
. 2018 Oct;
4(4).
PMID: 30302335
Clinically important deterioration (CID) is a novel composite end-point (lung function, health status, exacerbations) for assessing disease stability in patients with chronic obstructive pulmonary disease (COPD). We prospectively analysed CID...
19.
Lazaar A, Miller B, Tabberer M, Yonchuk J, Leidy N, Ambery C, et al.
Eur Respir J
. 2018 Aug;
52(4).
PMID: 30139779
No abstract available.
20.
Lipson D, Barnhart F, Brealey N, Brooks J, Criner G, Day N, et al.
N Engl J Med
. 2018 Apr;
378(18):1671-1680.
PMID: 29668352
Background: The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β-agonist (LABA), as compared with dual...